ClinicalTrials.gov
public full text
Public Domain
Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.
The purpose of this study is to evaluate if offering long-acting injectable cabotegravir (CAB-LA) as an additional HIV prevention choice among oral PrEP-experienced men who have sex with men (MSM) in France can significantly increase the sustained PrEP use over time and the PrEP coverage of at-risk sexual risk behaviors.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Guidelines on long-acting injectable cabotegravir for HIV prevention: web annex E: predicted effects of introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study#376871
- Express Testing and Same-day Initiation of PrEP Study#840479
- Airborne Preventive Measures to Reduce New TB Infections in Household Contacts#811916
- Investigating MPXV Viral Clearance in Mpox Cases and Secondary Attack Rate in Contacts#1044402
- Time-to-Tuberculosis disease diagnosis after completion of Tuberculosis preventive therapy among people living with HIV on Antiretroviral Therapy in Eastern Uganda: A retrospective cohort study#172246
Record · ID 917474
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive